为什么没有Erbitux®的生物仿制品?
Emmanuel Douez1, Valentina D'Atri2, Davy Guillarme3
1Pharmacy Department, Tours University Hospital, Tours, France; EA6295, Nanomédicaments et Nanosondes, Université de Tours, Tours, France.
Journal of pharmaceutical and biomedical analysis
|July 7, 2023
概括
埃尔比图克斯 (cetuximab) 的结构复杂性在证明生物相似性方面存在挑战,这解释了欧洲和美国没有批准的生物相似药. 此外,还探讨了替代生物更好的发展策略.
科学领域:
- 在瘤学瘤学.
- 生物制药开发 生物制药开发
- 免疫学 免疫学 免疫学
背景情况:
- 单克隆抗体 (mAb) 疗法在瘤学中至关重要,但成本昂贵.
- 生物类似药提供了经济替代品,并促进了竞争.
- 埃尔比图克斯 (cetuximab) 是一种抗EGFR mAb药物,用于治疗结直肠癌和头癌.
研究的目的:
- 调查为什么尽管专利到期,Erbitux仍然没有批准的生物仿制药.
- 分析Erbitux的结构复杂性及其对生物相似性的影响.
- 讨论生物改善作为一种替代的发展战略.
主要方法:
- 审查Erbitux的专利地位和市场数据.
- 对 mAbs. 的先进直角分析表征策略的分析.
- 讨论生物类似药物批准的监管障碍.
- 探索生物更好的发展途径.
主要成果:
- 埃尔比图克斯表现出独特的结构复杂性.
- 先进的分析表征揭示了证明生物相似性的风险.
- 美国和欧洲缺乏已批准的Erbitux生物类似药与这些复杂性有关.
- 生物改善者代表了一个可行的替代开发路线.
结论:
- 厄比图克斯的复杂结构给生物类似物开发带来了重大挑战.
- 证明像Erbitux这样复杂的mAbs的生物相似性需要复杂的分析方法.
- 生物改善剂为创新提供了一条途径,比参考产品提供更强大的治疗效益.
相关概念视频
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Factors Influencing Drug Absorption: Presystemic Elimination
265
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
265
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


